157,862 Shares in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets bought a new stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 157,862 shares of the company’s stock, valued at approximately $1,287,000. BNP Paribas Financial Markets owned about 0.28% of Ginkgo Bioworks as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in DNA. Wellington Wealth Strategies LLC. bought a new stake in Ginkgo Bioworks in the 2nd quarter worth approximately $41,000. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Ginkgo Bioworks by 1,606.9% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 234,836 shares of the company’s stock worth $79,000 after buying an additional 221,078 shares during the last quarter. PFG Investments LLC bought a new stake in shares of Ginkgo Bioworks in the third quarter worth $1,541,000. Algert Global LLC purchased a new stake in Ginkgo Bioworks during the second quarter valued at $36,000. Finally, Forbes J M & Co. LLP purchased a new position in Ginkgo Bioworks in the third quarter worth about $1,019,000. 78.63% of the stock is owned by institutional investors.

Ginkgo Bioworks Stock Down 8.3 %

DNA opened at $10.69 on Tuesday. The company has a market cap of $614.46 million, a P/E ratio of -0.82 and a beta of 1.17. Ginkgo Bioworks Holdings, Inc. has a 12-month low of $5.26 and a 12-month high of $75.20. The stock’s fifty day moving average price is $8.22.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. TD Cowen upped their price objective on Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, September 20th. BTIG Research upped their price target on Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a “sell” rating in a research report on Friday, August 23rd. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $4.58.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.